Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2026
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)Aman Chauhan, Heidi L Weiss, Charles Kunos, et al.
The Oncologist|October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2018
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine LymphomaJenna H Burton, Christina Mazcko, Amy LeBlanc, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083George Somlo, Paul H Frankel, Banu K Arun, et al.
Research Square|August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistanceJason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Pageof 20